For example, PIK3CA mutations were classified as Tier IIIA in colorectal cancer, reflecting limited evidence, but as Tier IIB in ovarian cancer, supported by early-phase trial data suggesting clinical benefit (Tables S7 and S10). This evidence concerns the gene PIK3CA and ovarian carcinoma.